These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12698178)

  • 1. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.
    Rustin GJ; Bradley C; Galbraith S; Stratford M; Loadman P; Waller S; Bellenger K; Gumbrell L; Folkes L; Halbert G;
    Br J Cancer; 2003 Apr; 88(8):1160-7. PubMed ID: 12698178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
    Jameson MB; Thompson PI; Baguley BC; Evans BD; Harvey VJ; Porter DJ; McCrystal MR; Small M; Bellenger K; Gumbrell L; Halbert GW; Kestell P;
    Br J Cancer; 2003 Jun; 88(12):1844-50. PubMed ID: 12799625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
    Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
    McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
    Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
    Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
    Jameson MB; Sharp DM; Sissingh JI; Hogg CR; Thompson PI; McKeage MJ; Jeffery M; Waller S; Acton G; Green C; Baguley BC
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2553-9. PubMed ID: 19387077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
    McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
    Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
    Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Zhou SF; Paxton JW; Tingle MD; Kestell P; Jameson MB; Thompson PI; Baguley BC
    Xenobiotica; 2001 May; 31(5):277-93. PubMed ID: 11491389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMXAA: an antivascular agent with multiple host responses.
    Baguley BC; Ching LM
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
    Wang LC; Ching LM; Paxton JW; Kestell P; Sutherland R; Zhuang L; Baguley BC
    Invest New Drugs; 2009 Jun; 27(3):280-4. PubMed ID: 18696010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
    Zhou S; Kestell P; Paxton JW
    Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.